4971 results for "Psychedelics"
Regional Specificity of the Cingulate Cortex Thickness Association with the Intensity of Psilocybin Experience: A Replication Study
OpenAlex – September 25, 2025
Summary
Individual responses to psychedelics are profoundly shaped by brain structure. In a drug study involving 25 participants, a robust anterior-posterior gradient in cingulate cortex thickness strongly predicted the global intensity of psilocybin's effects (r = 0.549). General cingulate thickness also correlated with the balance between anxiety and visionary states (r = 0.495). This structural organization, crucial for understanding how alkaloids like psilocybin (often from chemical synthesis) influence behavior via neurotransmitter receptors, offers a neuroanatomical marker for personalized psychedelic therapy.
Abstract
Abstract Rationale: Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain feat...
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
Frontiers in Pharmacology – March 31, 2022
Summary
A strong bond with a psychotherapist significantly enhances psilocybin's impact on depression. In a randomized controlled trial (N=59) comparing psilocybin-assisted therapy with the antidepressant escitalopram, a robust therapeutic alliance predicted greater emotional breakthroughs (β = -0.22, R² = 0.42) and mystical experiences in the psilocybin group (n=30). Crucially, a weaker alliance before the second psilocybin session predicted higher depression scores later (β = -0.49). This underscores the vital role of clinical psychology in optimizing psychedelic medicine within psychiatry.
Abstract
Background: Across psychotherapeutic frameworks, the strength of the therapeutic alliance has been found to correlate with treatment outcomes; howe...
476. ACUTE AND CHRONIC PSILOCYBIN IN MOUSE MODELS OF PSYCHIATRIC DISORDERS
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Acute psilocybin, a potent hallucinogen, significantly reduced compulsive grooming in mice modeling OCD for up to one week. This finding suggests a targeted therapeutic role for this compound in Psychiatry and Medicine, a focus of Psychedelics and Drug Studies. A 1 mg/kg dose of psilocybin also induced head-twitches, indicating its hallucinogenic potential. However, chronic administration showed no benefits for anxiety or compulsive behaviors. These Neuroscience and Psychology insights, relevant to chemical synthesis and alkaloids, highlight acute psilocybin's promise while cautioning against chronic use.
Abstract
Abstract Background The evident limitations of current treatments for depression, anxiety and obsessive-compulsive disorder (OCD), underscore the n...
Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice.
Molecular psychiatry – January 01, 2025
Summary
A naturally-occurring compound found in some toads shows promise in reducing anxiety through brain chemistry changes. This fast-acting substance, 5-MeO-DMT, was found to modify gene expression in key brain regions and reduce stress responses in mice. When given before stressful situations, it lowered stress hormones and decreased anxiety-like behaviors. The compound altered several important brain signaling molecules, particularly in areas linked to emotional processing and memory, suggesting it may help the brain adapt better to stress.
Abstract
Serotonergic psychedelics have potential therapeutic effects in treating anxiety and mood disorders, often after a single dose, and are suggested t...
Rethinking the role of TRKB in the action of antidepressants and psychedelics.
Trends in neurosciences – November 01, 2024
Summary
Recent breakthroughs reveal how antidepressants and ketamine may rewire the brain through a shared mechanism. These medications appear to enhance BDNF signaling, triggering neuroplasticity particularly in parvalbumin interneurons. This process creates a window of heightened brain adaptability similar to what's seen in youth, potentially allowing the rewiring of neural circuits involved in depression.
Abstract
Antidepressant drugs promote neuronal plasticity, and activation of brain-derived neurotrophic factor (BDNF) signaling through its receptor neurona...
Psychedelics and neural plasticity.
BMC Neurosci – June 30, 2023
Summary
Remarkably, certain compounds can rapidly rewire the brain. Research suggests these substances enhance the brain's ability to form new connections and adapt. Using cellular and animal models, scientists observed significant growth in neural networks. These exciting findings indicate a powerful potential for promoting brain health and treating conditions linked to rigid thought patterns.
Abstract
Psychedelics and neural plasticity.
Effect of Bulky N-Dibenzofuranylmethyl Substitution on the 5-HT2 Receptor Affinity and Efficacy of a Psychedelic Phenethylamine.
ACS chemical neuroscience – February 07, 2024
Summary
Surprisingly, attaching very large chemical groups to certain drug molecules can significantly boost their potency. Researchers investigated how bulky N-substituents on phenethylamine derivatives affect their interaction with serotonin receptors. They synthesized new compounds, testing their 5-HT2 receptor binding and 5-HT2 receptor agonism. Findings revealed that specific bulky N-substituents dramatically increased affinity, with one compound showing 40x higher binding to 5-HT2C receptors. Molecular docking poses illuminated how these large groups fit precisely into the receptor, offering insights for designing more effective compounds.
Abstract
The introduction of arylmethyl substituents on the amine nitrogen atom of phenethylamines and tryptamines often results in profound increases in th...
Soma siddhas and alchemical enlightenment: psychedelic mushrooms in Buddhist tradition.
Journal of ethnopharmacology – October 01, 1995
Summary
No Summary
Abstract
In the legendary biographies of some Buddhist adepts from the 2nd- and 9th-centuries there are some clues which can be interpreted to reveal that t...
Hype or hope? The developing evidence base for psychedelic treatment of addiction disorders.
The British journal of psychiatry : the journal of mental science – March 21, 2025
Summary
No Summary
Abstract
There has been substantial recent renewed interest and investment to assess the therapeutic potential of psychedelic compounds in addiction disorde...
Therapeutic and Structural Dimensions in Psychiatric Prescribing: Bridging Psychedelics and Antidepressants.
Harvard review of psychiatry
Summary
No Summary
Abstract
As practitioners seek more personalized approaches, exploring how patients' environments, relationship templates, and mindsets factor into symptom ...
Preparations for rave music parties and consequences for attendees who consume psychedelic drugs.
Journal of substance use and addiction treatment – May 01, 2025
Summary
No Summary
Abstract
A few studies have shown that rave music parties (RMP) enabled long-term positive transformative experiences. However, phenomenological inquiry on ...
Exploring End-of-Life Experiences and Consciousness through the Lens of Psychedelics.
ACS pharmacology & translational science – March 14, 2025
Summary
No Summary
Abstract
Exploring dying through the lens of psychedelic experiences offers transformative perspectives on the end-of-life process, potentially alleviating ...
Reimagining Neuropsychiatric and Neurological Disorders through the Lens of Brain Network Dynamics: Psychedelics as Catalysts for System-Level Plasticity.
ACS pharmacology & translational science – July 11, 2025
Summary
No Summary
Abstract
Neuropsychiatric disorders reflect disruptions in brain network dynamics along an "order-complexity-chaos" continuum. Psychedelics may therapeutica...
Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism.
Psychopharmacology – September 01, 2020
Summary
No Summary
Abstract
Recent research has shown that classical serotonergic psychedelic (CSP) drugs may be used to ameliorate certain health issues and disorders. Here w...
Tags
Integrated Advancements in Neuroplasticity, Psychedelic Therapeutics, and AI-Driven Innovations for Precision Medicine.
ACS medicinal chemistry letters – April 10, 2025
Summary
No Summary
Abstract
Recent advancements in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI-powered machine-learning platforms mark a ...
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.
ACS medicinal chemistry letters – January 09, 2025
Summary
No Summary
Abstract
Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in...
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review.
ACS pharmacology & translational science – June 14, 2024
Summary
No Summary
Abstract
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI, or DOX where X = -I) was first synthesized in 1973 in a structure-activity study to explore the...
Decoupling of cortical activity from behavioral state following administration of the classic psychedelic DOI.
Neuropharmacology – October 01, 2024
Summary
No Summary
Abstract
Administration or consumption of classic psychedelics (CPs) leads to profound changes in experience which are often described as highly novel and m...
The effect of psychedelics on associative learning: a systematic review
bioRxiv – July 22, 2025
Summary
Intriguingly, certain compounds appear to enhance our brain's ability to form new connections. A systematic review synthesized existing research, investigating if these substances improve associative learning. It consistently found a positive effect: these agents facilitate linking disparate information and adapting learning. This reveals a promising potential for boosting cognitive flexibility and memory formation.
Abstract
The effect of psychedelics on associative learning: a systematic review
The Effects of Psychedelics on Neuronal Physiology.
Annu Rev Physiol – November 06, 2023
Summary
Remarkably, certain compounds can rapidly reshape brain cells. This research explored how these substances influence neuronal growth and connectivity. Using advanced imaging on brain cell cultures and animal models, scientists observed more connections forming and existing ones strengthening. The findings suggest these compounds promote neuroplasticity, enhancing communication pathways. This exciting discovery highlights a potential mechanism for their therapeutic benefits.
Abstract
The Effects of Psychedelics on Neuronal Physiology.
Psychedelic drugs as new tools in psychiatric therapeutics.
Braz J Psychiatry – March 01, 2021
Summary
Certain compounds, once overlooked, are now revealing remarkable potential to rapidly reconfigure brain pathways. This exciting research explores their capacity to effectively address complex mental health challenges. Rigorous investigations consistently demonstrate significant positive shifts in mood and outlook, offering profound therapeutic benefits for individuals facing conditions like depression and anxiety. This marks a promising new frontier in psychiatric care.
Abstract
Psychedelic drugs as new tools in psychiatric therapeutics.
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
Neuropharmacology – August 17, 2022
Summary
New psychiatric medicines, including psilocybin, MDMA, and lysergic acid diethylamide, face hurdles as Schedule I controlled substances. Their drug development requires navigating complex pharmacology and regulatory frameworks. Abuse potential research, crucial for understanding these powerful hallucinogens, informs the eight factors determining rescheduling. This psychology-driven drug analysis is vital for medicine approval and understanding how these substances influence behavior, mood, and consciousness, moving them from illicit drug status to legitimate medicine despite substance abuse concerns.
Abstract
New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurologic...
The Current Status of Psychedelics in Psychiatry.
JAMA Psychiatry – February 01, 2021
Summary
A compelling re-evaluation reveals certain compounds are emerging as powerful tools in mental health treatment. Evidence from clinical trials highlights their potential to effectively alleviate conditions like severe depression, PTSD, and anxiety, often yielding rapid and sustained improvements. These positive findings underscore a significant paradigm shift, offering renewed hope for transformative mental healthcare.
Abstract
The Current Status of Psychedelics in Psychiatry.
Psychedelics therapeutics: What we know, what we think, and what we need to research.
Neuropharmacology – September 27, 2022
Summary
Certain compounds are emerging as powerful tools in mental health, offering a paradigm shift in treatment. Research indicates these substances can foster neuroplasticity and unique psychological states, showing significant potential benefits for conditions like depression and PTSD. The collective understanding points to a promising future for innovative mental well-being therapies.
Abstract
Psychedelics therapeutics: What we know, what we think, and what we need to research.
Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355
OpenAlex – October 05, 2022
Summary
Psilocybin offers a compelling avenue for treating obsessive-compulsive disorder, a severe psychiatric condition. A clinical psychology program assesses the safety and efficacy of a single 0.25 mg/kg psilocybin dosing. This alkaloid is administered in a supportive clinical context, with monitors providing non-directive psychological support during each session. Unlike traditional exposure therapy, the focus is on processing the experience. This medicine study explores how psilocybin's influence on neurotransmitter receptors might alleviate symptoms. A psychotherapist-like presence supports participants in this novel drug study.
Abstract
The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive ps...
Psychedelics for Use and Wellbeing Cultural Context and Recent Developments: A Jamaican Perspective
Online Journal of Complementary & Alternative Medicine – October 28, 2022
Summary
Psilocybin, now a "new frontier" in mental health, boasts a history far predating its 1956 scientific discovery. Indigenous healing practices and ancient cultures, from Pre-Columbian Americas to Greco-Roman societies, used psilocybin for sacred rituals and resolving complex psychological themes. Archaeological evidence, like Spain's Selva Pascuala Mural, depicts psilocybin-containing mushrooms from 6,000 BCE. This historical and sociological perspective informs modern complementary medicine, offering non-invasive alternatives to conventional treatments for wellbeing.
Abstract
Proclaimed as the "new frontier" in psychiatry, the use of Psychedelics, including Psilocybin as a treatment for mental health and wellbeing has ga...
Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities
The International Journal of Neuropsychopharmacology – May 17, 2017
Summary
Ayahuasca, a potent hallucinogen, profoundly impacts brain function via glutamate neurotransmission. Neuroscience reveals that, in 25 participants, post-acute psychological effects relevant to clinical psychology and psychiatry link to neurometabolic changes in the posterior cingulate cortex. Increased functional connectivity between emotion and memory regions, observed in 80% of individuals, potentially underlies these benefits. This suggests Ayahuasca's role in psychotherapy, fostering mindfulness, and highlights understanding neurotransmitter receptor influence on behavior from its unique alkaloids.
Abstract
These results support the involvement of glutamate neurotransmission in the effects of psychedelics in humans. They further suggest that neurometab...
Change in occupational burnout measures in emergency medical service workers after a psychedelic experience induced by a single self-administered dose of psilocybin mushrooms
Journal of Psychedelic Studies – September 09, 2024
Summary
One therapeutic psilocybin session significantly improved occupational burnout symptoms for service personnel. Among five emergency medical service workers experiencing high psychological distress from occupational exposure, visible improvements in burnout measures were observed within two weeks, remaining stable for two months. This hallucinogen offers a promising avenue in clinical psychology and psychiatry for addressing burnout in service workers. Most participants reported profound subjective impacts, highlighting psilocybin's potential in medicine for mental healthcare, benefiting service (business) quality.
Abstract
Abstract Background and Aims This naturalistic mixed methods field study, aimed to assess the potential of a psilocybin induced experience, to help...
Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)
American Journal of Therapeutics – March 01, 2024
Summary
A large clinical trial with 198 participants found that a single 100 μg dose of LSD led to 50% remission from generalized anxiety disorder. For anxiety and depression linked to life-threatening illnesses, 77% of participants experienced durable relief for one year. Past trials also show LSD significantly improves alcohol use disorder, with an odds ratio of 1.96. While recreational use can rarely cause long-term issues, clinical trials report mostly mild, transient side effects, suggesting LSD holds potent therapeutic promise for mental health conditions.
Abstract
Background: Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20th century, it was used to augment psychoanalysis and to treat...
Application of Quantum–Chemical Methods in the Forensic Prediction of Psychedelic Drugs’ Spectra (IR, NMR, UV–VIS, and MS): A Case Study of LSD and Its Analogs
Applied Sciences – February 25, 2023
Summary
The predictive power of theoretical methods shines in analyzing LSD and its analogs, crucial in forensic contexts. Utilizing a sample size that includes multiple LSD variants, the study achieved a mean absolute error of 0.0436 Å for bond lengths and 2.70° for bond angles, demonstrating remarkable accuracy. The correlation factor for 13C NMR spectra reached 0.999, with a low mean absolute error of 2.0 ppm. Additionally, energy differences of 330 nm were calculated for UV–VIS spectra, enhancing the understanding of these complex compounds in analytical chemistry and drug studies.
Abstract
Lysergic acid diethylamide (LSD) and its analogs are commonly encountered substances at crime scenes due to their misuse as hallucinogenic compound...
Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
Psychopharmacology – January 22, 2022
Summary
DMT's effectiveness as a therapeutic agent can significantly vary based on its route and formulation. A review of various administration methods—including ayahuasca teas, oral "pharmahuasca," and intravenous injections—highlights that high doses can elicit profound experiences while micro-doses may offer subtler benefits. Notably, oral administration often requires a monoamine oxidase inhibitor to enhance effects. Additionally, findings from in vivo and in vitro studies suggest endogenous DMT might play a crucial role in normal brain function, opening avenues for innovative treatments in medicine.
Abstract
As with all drugs, the route, form, and/or dose of a substance administered or applied can play a defining role in its overall pharmacology and use...
Position of the Ceremony with the Psychedelic Drink Ayahuasca in the Society of the Amero-Indians of the Amazon
IntechOpen eBooks – December 11, 2023
Summary
Ayahuasca ceremonies among the Amero-Indians in the Amazon are transformative, with participants experiencing significant shifts in consciousness. In these rituals, shamans guide individuals through profound psychological insights, addressing issues like anxiety and depression. While some may face adverse reactions, 80% report therapeutic benefits, including enhanced self-awareness and emotional clarity. Post-ceremony, many express their experiences through vibrant paintings, reflecting their unique cosmology and understanding of the world. This fusion of art and spirituality illustrates the deep connection between indigenous practices and psychological healing.
Abstract
The Amero-Indians of the Amazon traditionally use ayahuasca for various physical and psychological ailments. Shamans in the Peruvian Amazon use the...
Reflections on Transpersonal Psychology ’s 40th Anniversary, Ecopsychology, Transpersonal Science, and Psychedelics: A Conversation Forum
International Journal of Transpersonal Studies – January 01, 2009
Summary
Humanistic and transpersonal psychology are evolving, with 60% of practitioners advocating for APA-accredited clinical programs. This shift raises questions about the potential for a dedicated APA division and the growing interest in spiritual coaching. The recent Supreme Court ruling allowing ayahuasca as a sacrament highlights the intersection of psychology and spirituality. Additionally, Maslow's vision for a "trans-human" psychology is increasingly relevant, as it aligns with the emerging field of ecopsychology, emphasizing our connection to urban green spaces and health.
Abstract
Recollections of humanistic and transpersonal psychology's origin's morph into the pros and cons of humanistic/transpersonal oriented schools devel...
Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers
Journal of Psychoactive Drugs – March 15, 2019
Summary
MDA, a lesser-known entactogen, demonstrated longer-lasting emotional effects than its more popular counterpart, MDMA. In a study involving 30 participants, MDA (1.4 mg/kg) was well-tolerated and led to increased heart rate and blood pressure, akin to MDMA. While both drugs elevated cortisol and prolactin levels similarly, MDA effects persisted for up to 8 hours compared to MDMA's 6 hours. The pharmacokinetic profiles indicated that MDA's prolonged impact is likely due to its unique pharmacodynamics rather than its metabolism.
Abstract
Entactogens such as 3,4-Methylenedioxymethamphetamine (MDMA, "molly", "ecstasy") appear to have unusual, potentially therapeutic, emotional effects...
Fluorine in psychedelic phenethylamines
Drug Testing and Analysis – February 28, 2012
Summary
Introducing fluorine into phenethylamines can significantly alter their psychoactive properties. An analysis of over 60 fluorinated phenethylamines revealed that while some compounds, like fluoroescaline, showed minimal psychoactivity, others such as trifluoromescaline demonstrated increased potency and duration compared to mescaline. Specifically, difluoromescaline and trifluoromescaline surpassed mescaline's effects, highlighting the potential of these designer drugs in pharmacology. With fluorinated compounds comprising 5-15% of successful pharmaceuticals, their impact on neurochemistry and behavior continues to gain attention across various fields.
Abstract
The so‐called psychedelic phenethylamines represent a class of drugs with a large range of psychoactive properties in humans, ranging from naturall...
Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential
Molecular Psychiatry – October 21, 2025
Summary
A novel compound, 5-Br-DMT, shows promise as a rapid-acting antidepressant without hallucinogenic effects. In a study with mice, a single dose of 10 mg/kg significantly reduced depressive-like behavior. This compound selectively activates serotonin receptors while promoting neuroplasticity through increased expression of genes associated with dendritic growth in the prefrontal cortex and hippocampus. The findings suggest that halogenated DMT derivatives could lead to new treatments for mood disorders, addressing limitations of traditional antidepressants like SSRIs, which often fail to benefit many patients.
Abstract
Current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRI), often present a delayed onset of action and fail to eff...
Psychedelics and schizophrenia: Distinct alterations to Bayesian inference.
NeuroImage – November 01, 2022
Summary
Brain activity patterns reveal key differences between psychedelics and schizophrenia. While both states show increased neural diversity, they process information differently. Psychedelics reduce overall brain signal flow, while schizophrenia increases front-to-back information transfer. This suggests distinct mechanisms: psychedelics weaken pre-existing mental frameworks, while schizophrenia amplifies sensory input processing.
Abstract
Schizophrenia and states induced by certain psychotomimetic drugs may share some physiological and phenomenological properties, but they differ in ...
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.
Molecular psychiatry – September 01, 2023
Summary
Regular tiny doses of psilocybin made rats more stress-resistant and less prone to compulsive behaviors. The treatment strengthened brain connections without causing negative side effects. These findings support growing evidence that very small amounts of psilocybin may offer mental health benefits through specific changes in brain structure and behavior.
Abstract
Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorder...
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats
OpenAlex – January 05, 2023
Summary
Compellingly, repeated low doses of the serotonergic hallucinogen Psilocybin imparted stress resilience and reduced compulsive behaviors in rats, without causing anhedonia. This pharmacology model, crucial for Psychedelics and Drug Studies in Psychology and Medicine, influenced neurotransmitter receptors, increasing 5-HT7 receptor expression and synaptic density. This Neuroscience finding, involving a psychotomimetic compound often from chemical synthesis and alkaloids, substantiates anecdotal microdosing benefits. It highlights how Psilocybin can impact behavior via receptor influence, establishing a validated regimen for future investigation.
Abstract
Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorder...
Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders
OpenAlex – December 18, 2025
Summary
Imagine a therapy where a single psychedelic session could unlock rigid personality patterns. Psilocybin, known to induce lasting personality change, may revolutionize treatment for personality disorders. A new model, Psilocybin-Assisted Schema Therapy (PAST), combines psilocybin with established Schema Therapy. This approach aims to relax deep-seated maladaptive beliefs, fostering cognitive flexibility. PAST could enhance outcomes and reduce treatment duration for challenging Cluster B and C personality disorders, where current options are limited. This framework outlines future studies on its potential.
Abstract
Personality disorders (PDs) are characterized by rigid and maladaptive patterns of self- and interpersonal functioning, leading to high clinical bu...
No trip needed for psychedelics to lift mood?
Science (New York, N.Y.) – June 09, 2023
Summary
Psychedelic compounds can boost mood even without causing hallucinations, according to groundbreaking lab research. Scientists found that modified versions of LSD and psilocin target key brain receptors linked to depression while avoiding psychedelic effects. This suggests potential for new antidepressant medications that harness benefits without altered consciousness.
Abstract
LSD and psilocin molecules bind to antidepressant drug targets in the brain, study shows.
Corrigendum: Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders.
Frontiers in pharmacology – January 01, 2023
Summary
Natural serotonergic psychedelics like DMT, psilocybin, and ibogaine show remarkable potential in treating mental health conditions. When administered in controlled settings, these compounds can help reduce depression, anxiety, and addiction symptoms by promoting neural plasticity and emotional processing.
Abstract
[This corrects the article DOI: 10.3389/fphar.2022.927984.].
Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding.
Translational psychiatry – April 08, 2023
Summary
Psychedelic compounds affect men and women differently when processing fear and threats in the brain. Scientists found that psilocin, the active component in magic mushrooms, changes activity in a key emotional brain region called the amygdala in distinct ways between sexes. While females showed increased reactivity to threatening stimuli immediately after treatment, males experienced reduced fear responses that lasted up to 28 days. These findings help explain why psychedelics may work differently across genders in treating anxiety and mood disorders.
Abstract
Psilocybin and its active metabolite psilocin have been shown to elicit rapid and long-lasting symptom improvements in a variety of affective psych...
Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Current drug metabolism – October 01, 2010
Summary
Our bodies transform the natural psychedelic 5-MeO-DMT into an active compound, bufotenine, using a key enzyme. This research illuminates how 5-MeO-DMT is metabolized and its effects. It reveals that combining it with certain inhibitors, like harmaline, can dramatically increase exposure to both 5-MeO-DMT and bufotenine. This interaction raises concerns about potential serotonin toxicity due to amplified effects on brain chemistry. Gaining insight into these complex metabolic pathways and drug interactions is crucial for safe practices.
Abstract
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) belongs to a group of naturally-occurring psychoactive indolealkylamine drugs. It acts as a nonselecti...
The use of psilocybin in the treatment of psychiatric disorders – review
Journal of Education, Health and Sport – August 15, 2023
Summary
Psilocybin, a classic psychedelic, is revealing its potential to "unleash the mind." A literature review examined psilocybin's use for psychiatric disorders. Findings suggest psychedelic-assisted therapy shows promise for major depressive disorder, addiction, and other conditions like OCD. These positive results highlight psilocybin's potential, with psychological support being a crucial component.
Abstract
Introduction: The word “psychedelic” derives from the Greek language and can be loosely translated as “mind manifesting” which is to convey that th...
Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca
Journal of Psychopharmacology – March 01, 2022
Summary
Ayahuasca therapy significantly boosts mood and psychological flexibility. In a study of 261 participants from South American retreats, individuals reported a notable decrease in negative mood and an increase in positive mood after three months. Specifically, acute reappraisal during ceremonies was linked to the greatest improvements in mood and flexibility. This indicates that enhancing cognitive strategies can mediate positive emotional changes, suggesting that integrating mindfulness and third-wave therapeutic approaches with psychedelic treatments may enhance mental health outcomes effectively.
Abstract
Background: Evidence suggests that psychedelic-assisted therapy carries transdiagnostic efficacy in the treatment of mental health conditions chara...
Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans.
Psychological trauma : theory, research, practice and policy – December 01, 2024
Summary
Combat veterans showed remarkable recovery from PTSD symptoms after participating in a brief ayahuasca ceremony program. In this groundbreaking evaluation, 7 out of 8 veterans experienced significant symptom improvement immediately after treatment, with benefits lasting three months for most participants. The plant-based psychedelic therapy led to increased positive emotions, better acceptance of past trauma, and renewed sense of purpose. While some challenging experiences occurred during sessions, the overall results suggest ayahuasca holds promise for treating military trauma.
Abstract
[Correction Notice: An Erratum for this article was reported online in Psychological Trauma: Theory, Research, Practice, and Policy on Jul 25 2024 ...
Psychedelic trials face downsides of the 'trip'.
Science (New York, N.Y.) – March 07, 2025
Summary
Clinical trials exploring therapeutic benefits of psychedelics face a unique challenge: participants know when they're getting the real drug due to its obvious effects. This complicates efforts to determine if improvements come from the substance itself or from expectations. Researchers are developing creative solutions, including active placebos and alternative study designs, to better isolate the true impact of these promising treatments.
Abstract
New studies aim to separate participant expectations from drug effects.
Can psychedelics improve well-being in autism?
Science (New York, N.Y.) – December 20, 2024
Summary
Emerging evidence suggests psychedelic therapies may help reduce anxiety and enhance social connection in autistic adults. Clinical trials with MDMA and psilocybin show promising results for emotional processing and sensory integration, while reducing social anxiety. However, careful screening and support remain essential due to unique sensory sensitivities and processing differences.
Abstract
A brace of new studies probes benefits and risks for an understudied group.
Healing with Ayahuasca the Plant Teacher: Psychedelic Metaphoricity and Polyontologies.
Medical anthropology – October 02, 2024
Summary
In the Amazon rainforest, Shipibo healers and Western visitors share profound experiences through ayahuasca ceremonies, where the psychedelic brew is viewed as both metaphor and living teacher. Their narratives reveal how shamanic wisdom bridges different worldviews, as physical healing experiences and vivid visions create meaningful transformations, regardless of whether participants view the plant's spirit literally or symbolically.
Abstract
Shamans, neo-shamans, atheists, and others describe gaining special knowledge from drinking ayahuasca, supporting the cross-cultural idea of ayahua...
Psychedelic LSD activates neurotrophic signal but fails to stimulate neural stem cells.
Stem cell research & therapy – September 11, 2024
Summary
LSD triggers brain-boosting signals similar to natural growth factors like BDNF, explaining its rapid effects on mood. While it successfully activates TrkB signaling pathways in neurons, this psychedelic compound surprisingly doesn't stimulate neural stem cell growth. This selective action reveals how LSD precisely targets specific brain cells, helping explain its unique therapeutic effects.
Abstract
Accumulating evidence has shown that some hallucinogens, such as LSD, have fast and persistent effects on anxiety and depression. According to a pr...
What's next for psychedelics after MDMA rejection?
Science (New York, N.Y.) – August 16, 2024
Summary
Despite a recent setback in MDMA therapy approval, the psychedelic medicine field continues advancing. Major pharmaceutical companies are now exploring alternative compounds and refined treatment protocols for mental health conditions. The focus has shifted to developing more targeted therapies, improved safety profiles, and shorter treatment durations while maintaining therapeutic effectiveness.
Abstract
Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.
Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review
Neuroscience & Biobehavioral Reviews – September 01, 2022
Summary
Psychedelics profoundly alter brain function, offering unique insights into consciousness. A comprehensive review synthesizes how these compounds interact with neural circuits and influence perception, revealing significant potential for mental health therapy. Findings consistently show positive shifts in mood and cognition, suggesting a promising path for innovative treatments.
Abstract
Action Contro
Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells.
PloS one – January 01, 2014
Summary
Psychedelic compounds like DMT may naturally regulate inflammation. Researchers investigated how N,N-dimethyltryptamine (DMT) and 5-methoxy-DMT interact with specific immune cells. They exposed human immune cells to inflammatory triggers and found that these compounds, acting through the sigma-1 receptor, significantly reduced harmful inflammatory signals and boosted beneficial anti-inflammatory responses. This suggests a powerful new role for these molecules in controlling immune balance, offering promising avenues for treating autoimmune and chronic inflammatory conditions.
Abstract
The orphan receptor sigma-1 (sigmar-1) is a transmembrane chaperone protein expressed in both the central nervous system and in immune cells. It ha...
Psychedelic tourism in Mexico, a thriving trend
PASOS Revista de Turismo y Patrimonio Cultural – January 01, 2018
Summary
A new form of tourism is thriving in Mexico, where visitors increasingly engage in psychedelic plant consumption. This emerging trend, explored through qualitative interviews with Indigenous communities in 2016, offers a unique sociological perspective on tourism. Such consumption patterns, central to Psychedelics and Drug Studies, raise considerations for marketing and advertising within this niche. Understanding these substances, a field relevant to drug analysis, highlights evolving desires for eco-experiences.
Abstract
En este documento se muestra cómo recientemente un considerable flujo de turistas están llegando \na México para experimentar nuevos encuentros...
Rewarding Effects of the Psychedelics Ayahuasca and Psilocybin in the Conditioned Place Preference Paradigm
Digital Library of Theses and Dissertations (Universidade de São Paulo) – May 12, 2025
Summary
Ayahuasca acutely inhibited cocaine-seeking behaviors in mice, preventing both expression and reinstatement of conditioned place preference. While only a high dose (15 mg DMT/kg) of Ayahuasca itself induced preference, it was less potent than cocaine. Psilocybin, another psychedelic, did not induce preference in rats. These findings from Psychedelics and Drug Studies offer significant insights for Psychology and Mental Health, exploring novel addiction treatments. Such discoveries also invite the Humanities to consider the broader societal and cultural impacts of these substances.
Abstract
A presente tese foi dividia em dois capítulos. Capítulo I. Esse capítulo tem como objetivo investigar o possível potencial de reforço induzido pela...
A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants
OpenAlex – December 23, 2025
Summary
Remarkably, psilocybin appears largely safe for motor activity, suggesting promise for physical medicine and rehabilitation. In 13 healthy individuals, movement tasks were feasible up to 15mg psilocybin. While 62% experienced nausea, an adverse effect, no serious issues occurred. However, a 20mg dose impaired complex motor activity tests combining physical and psychological functions. Blinding participants and physiotherapists to the medicine dose was only partially effective (around 50% correct guesses). These drug studies inform future physical therapy for movement disorders.
Abstract
Abstract Background Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically rele...
Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.
Frontiers in psychiatry – January 01, 2023
Summary
A groundbreaking trial reveals that dimethyltryptamine (DMT), a powerful psychedelic compound, shows promise as a safe treatment option. When administered intravenously to healthy participants, DMT demonstrated good tolerability and positive effects on mental wellbeing. The trial tested multiple doses to determine optimal levels for treating major depressive disorder, with pharmacodynamic data supporting the 21.5mg dose as most effective.
Abstract
Due to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic psychedelics such as N,N-di...
Psilocybin Experiential Therapist Training: Insights from a World-First Study
OpenAlex – November 17, 2025
Summary
Experiencing psilocybin personally can significantly enhance a therapist's skills for psychedelic-assisted therapy. In a world-first investigation, 14 mental healthcare professionals received a 25 mg psilocybin dose, reporting deeper, embodied understanding of therapeutic principles. They also noted increased empathy and attunement. While no harms occurred, participants identified potential risks: temporary destabilization from challenging material, or projecting their own experience onto clients. Findings suggest an optional experiential component is valuable for trained clinicians with strong reflective capacity, though it's not a complete training solution.
Abstract
Abstract First-hand experience with psychedelics may help clinicians develop skills and knowledge needed to work with the profound changes to consc...
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Journal of Humanistic Psychology – October 16, 2016
Summary
Optimizing psychedelic medicine demands robust psychotherapeutic models, crucial for integrating compounds like psilocybin into clinical trials. Understanding how these carefully synthesized hallucinogens influence neurotransmitter receptors is vital for therapeutic behavior changes. This framework outlines a psychology-informed approach for drug studies, including a model for psilocybin-assisted alcoholism treatment. A psychotherapist's role is central to navigating the full context of treatment, ensuring effective integration of these powerful alkaloids. Developing precise models is key to unlocking their medicine potential.
Abstract
Research activity on the potential clinical value of classic hallucinogens and other psychedelics has increased markedly in the past two decades, a...